Relationship between erythropoietin administration and alterations of renin-angiotensin-aldosterone.
The effect of erythropoietin (EPO) administration on the responsiveness of the renin-angiotensin-aldosterone system (RAAS) has not been established. Because patients with chronic kidney disease (CKD) require EPO for their management as CKD progresses, it is important to ascertain whether EPO treatment alters the RAAS. If EPO administration stimulates renin-angiotensin or aldosterone (ALDO) this intervention would mediate cardiovascular and renal injury, and consequently promote cardiovascular events and/or exacerbate the progression of renal disease. We reviewed the available publications investigating the effects of EPO on the RAAS. In CKD patients following EPO administration plasma renin activity (PRA) was unchanged in all three and ALDO was not altered in the two studies in which it was determined. In end-stage renal disease (ESRD) patients undergoing dialysis following EPO administration, four studies reported a decrease in PRA levels whereas the remaining nine disclosed no change in PRA levels. The changes in ALDO levels after EPO administration in ESRD patients were discrepant with two studies reporting an increase, two reporting a decrease and the remaining three disclosing no change.
Rosario
Reinaldo
R
Division of Nephrology and Hypertension, Cleveland Clinic Florida, Weston, Florida, USA.
Epstein
Murray
M
D004921:Erythropoietin / Q000008:administration & dosage*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D012083:Renin / Q000097:blood*; D012084:Renin-Angiotensin System / Q000187:drug effects*
D004921:Erythropoietin; D012083:Renin